Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial

Indian Journal of Pharmacology

Volumn 46, Issue 1, 2014, Pages 24-28

  Ghosh, Arijit ^a   Sengupta, Nilanjan ^a   Sahana, Pranab ^a   Giri, Debasis ^a   Sengupta, Parama ^a   Das, Nina ^a  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Bromocriptine; Diabetes mellitus; Metformin

Indexed keywords

BROMOCRIPTINE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

BROMOCRIPTINE; DIABETES MELLITUS; METFORMIN;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY WEIGHT; BROMOCRIPTINE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; YOUNG ADULT;

EID: 84893325293     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.125160     Document Type: Article

References (15)

1. Bennet PH. Definition, diagnosis and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC, editors. Joslins Diabetes Mellitus. 13th ed. Philadelphia: Lea Febiger Publisher; 1994. p. 200.
2. Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Indian J Endocrinol Metab 2011;15 (Suppl1):S33-9.
3. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A randomized, doubleblind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007;7:3.
4. Hennesy T. Old Parkinson's drug tweaked into diabetes treatment. The Associated Press; 2009.
5. Via MA, Chandra H, Araki T, Ponteza MW, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2010;3: 43-8.
6. Dave DJ. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J Pharmacol Pharmacother 2011;2: 230-5.
7. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes care 2008;31 Suppl 1:S12-54.
8. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis and management. Lancet 2000;356: 1255-9.
9. DeFronzo RA. Bromocriptine: A sympatholytic, D2-Dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011;34: 789-94.
10. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19: 667-70.
11. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999;8: 1683-707.
12. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care 2000;23: 1154-61.
13. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33: 1503-8.
14. Scranton RE, Ezrokhi M, Gaziano JM, Cincotta AH. Quick release bromocriptine (Cycloset TM) improves glycaemic control in patients with diabetes failing metformin/sulfonylurea combination therapy. Diabetologia 2008;51:S372-3.
15. Cincotta AH, Ezrokhi M, Scranton R. Cycloset (Quick-Release Bromocriptine Mesylate), a novel centrally acting treatment for type 2 diabetes. Diabetologia 2008;51:S22.